[Asia Economy Reporter Kum Boryeong] Huons Global announced on the 30th that it has completed the Phase 1 clinical trial for the treatment of post-stroke upper limb muscle spasticity using Liztox Injection 100 units (Clostridium botulinum toxin type A).
The clinical trial approval institution was the Ministry of Food and Drug Safety, and the clinical trial was conducted at a single institution, Seoul Asan Medical Center.
Huons Global stated, "We aimed to evaluate the safety and efficacy of Liztox Injection administered to patients confirmed with upper limb muscle spasticity after stroke onset. Compared to the safety profile of existing botulinum toxin type A treatments, no specific adverse events were observed with the administration of Liztox Injection 100 units," adding, "Clinically significant reduction in muscle tone and other improvements in spasticity were confirmed."
Based on the results of this Phase 1 clinical study, Huons Global plans to apply to the Ministry of Food and Drug Safety for the next phase of clinical trials.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
